ReviewInternational journal of clinical pharmacy2019
Tigecycline-induced coagulopathy: a literature review.
Review in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Hemorrhagic Pneumonia Caused byMedicina (Kaunas, Lithuania) · 2024Pooled it
- Pooled it
- Hypofibrinogenemia Induced by Eravacycline: A Rare but Serious Adverse Effect of a Novel Antimicrobial Agent.Cureus · 2026Article
- Construction and temporal external validation of interpretable machine-learning models for predicting tigecycline-associated hypofibrinogenemia.European journal of clinical pharmacology · 2026Article
- Tigecycline-Associated Hypofibrinogenemia and Major Bleeding: Incidence, Predictors, and Clinical Outcomes in a Retrospective Cohort.Infection and drug resistance · 2026Article
- Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.International journal of clinical pharmacy · 2025Article
- Impact of Drugs Used in Intensive Care on Routine Coagulation Testing.Diagnostics (Basel, Switzerland) · 2025Review
- Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Linezolid Associated Asymptomatic Hypoglycemia in a Patient with Advanced Gynecologic Cancer: A Case Report and Literature Review.International medical case reports journal · 2025Article
- LC-MS-Based Serum Metabolomic Analysis Predicts the Risk of Tigecycline-Induced Coagulopathy in Critically Ill Patients.Drug design, development and therapy · 2025Observational
- Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients.Frontiers in pharmacology · 2025Article
- Impact of Tigecycline on Coagulation in Severe Infections and Effect of Vitamin K1 Intervention: A Retrospective Single-Center Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Tigecycline-induced coagulation gene prognostic prediction model and intestinal flora signature in AML.Frontiers in immunology · 2024Article
- Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- Prediction and analysis of toxic and side effects of tigecycline based on deep learning.Frontiers in microbiology · 2024Article
- Partial Purification and Biochemical Evaluation of Protease Fraction (MA-1) fromAntioxidants (Basel, Switzerland) · 2023Article
- Tigecycline Immunodetection Using Developed Group-Specific and Selective Antibodies for Drug Monitoring Purposes.Biosensors · 2023Article
- Clinical Characteristics, Drug Resistance, and Risk Factors for Death ofInfection and drug resistance · 2023Article
- Development and Validation of a Nomogram for Predicting Tigecycline-Related Coagulopathy: A Retrospective Cohort Study.Infection and drug resistance · 2023Article
- Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients.Disease markers · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Several adverse reactions to tigecycline, which is widely used in patients with severe infections, have been documented. Coagulopathy is a lesser known side effect of tigecycline. Aim of the review We summarize the characteristics, possible mechanisms, and treatment of tigecycline-induced coagulopathy. Method PubMed, Ovid, Embase, ISI Web of Knowledge, CNKI, and Wanfang were searched up to March 5, 2019. All articles concerning coagulopathy induced by tigecycline were included. The article types and languages were not limited. The retrieved articles were screened by two experienced clinicians by reading the titles, abstracts, and full texts. Results Ultimately, 17 articles were targeted, including 13 case reports and 4 retrospective observational studies. Tigecycline-induced coagulopathy usually manifests as the dose-dependent prolongation of prothrombin time and activated partial thromboplastin time and a reduction in the fibrinogen level. Tigecycline and its metabolites may have multiple effects on coagulation, influencing the extrinsic or intrinsic pathway and even the common pathway. There is no specific treatment for tigecycline-induced coagulopathy, but it can be reversed by withdrawing tigecycline. Conclusion Tigecycline acts on the coagulation system in a dose-dependent manner, and the most severe adverse event is bleeding. Overdose and prolonged use should be avoided, suspected coagulopathy must be recognized in time, and tigecycline should be withdrawn to prevent severe adverse events. Also, drug clearance disorders can develop in patients with liver and/or renal dysfunction. For patients with severe hepatic or renal impairment, the maintenance dose should be reduced, and indicators of coagulation function should be closely monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.